Cardiogenic Shock Intravascular Cooling Trial

Cardiogenic Shock Clinical Trial

— CHILL-SHOCK  

Official title:

Cardiogenic Shock Intravascular Cooling Trial (CHILL-SHOCK)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03141255
• Other study ID #: IRB16-1728
• Status: Completed
• Phase: N/A
• Start date: November 6, 2017
• Est. completion date: November 1, 2021

Study information

• Verified date: March 2023
• Source: University of Chicago
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to compare patients with cardiogenic shock who receive standard therapy plus therapeutic hypothermia (TH) to patients with cardiogenic shock who receive standard medical therapy alone in order to assess the safety of TH in patients with cardiogenic shock. This study will also help understand the physiologic effects of TH in patients with cardiogenic shock. This will be a pilot study to establish the initial safety of TH and to assess tolerability of TH in this patient population.

Description:

This is an unblinded pilot study of 20 patients randomized to either TH plus standard medical care or to standard medical care alone. All patients will undergo pulmonary artery (PA) catheter placement as part of the standard of care for management of cardiogenic shock. Data from the PA catheter is vital in monitoring real-time hemodynamics, initiating vasopressors/inotropes, assessing the response to the therapies, and possible need for escalation of therapy. For patients randomized to TH, cooling to 32-34°C will then be initiated and maintained for 24 hours using the FDA-approved Intravascular Temperature Management (IVTM™) System with the 9.3 French Quattro® Catheter. The IVTM™ System along with the Quattro® Catheter are currently FDA-approved for use in cardiac surgery patients to achieve and maintain normothermia during surgery and in recovery and to induce, maintain, and reverse mild hypothermia in neurosurgery patients during surgery and in recovery. The IVTM™ System and Quattro® Catheter are not, however, currently FDA-approved to achieve therapeutic hypothermia in cardiogenic shock patients. TH is achieved by circulating normal saline in a closed system through the catheter. The temperature is measured and adjustments are made by the thermal regulation system to automatically maintain target temperature. The target temperature is achieved within 2-3 hours of initiation of TH. Rewarming is accomplished using the same balloon catheter system and heat exchange occurs without infusion of any saline or fluids. Standard medical therapy for all patients will be based on the current recommendations for management of cardiogenic shock. This includes inotropic therapy for cardiac support, vasopressor therapy to achieve target blood pressure, diuretics for volume removal, and mechanical circulatory support as clinically indicated. Laboratory, echocardiographic, and hemodynamic parameters will be obtained for patients prior to randomization, after 18-24 hours post-randomization, and after 48-96 hours post-randomization. Core temperature will be measured via either thermal tip at the end of a transurethral urinary catheter or endotracheal temperature probe in intubated patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: November 1, 2021
• Est. primary completion date: November 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 89 Years

Eligibility

Inclusion Criteria:

1. Cardiogenic shock

1. Systolic blood pressure <90mmHg for at least 30 minutes

2. Cardiac Index < 2.2 L/min/m2

3. Pulmonary capillary wedge pressure (PCWP) = 15mmHg

4. Need for central venous access, vasopressors, inotropes and/or mechanical circulatory support (i.e. intra-aortic balloon pump, Impella®, ECMO) to maintain systolic blood pressure = 90mmHg

2. Etiology of shock

1. Acute coronary syndromes (STEMI, NSTEMI, or UA)

2. Ischemic or non-ischemic cardiomyopathy

3. Myocarditis

4. Hypertrophic cardiomyopathy

5. Stress-induced cardiomyopathy

6. Peripartum cardiomyopathy

7. Cardiogenic shock in a patient with heart failure with preserved ejection fraction

3. Age = 18 years AND = 89 years

4. Admission to the University of Chicago Coronary Care Unit

Exclusion Criteria:

1. Baseline heart rate < 60 beats per minute

2. Baseline temperatures < 35°C

3. Recent cardiotomy

4. History of cardiac transplantation

5. Current pregnancy

6. Contraindication to 9.3 French femoral venous access for placement of intravascular cooling catheter

7. Hospice designation (either currently in hospice or previously enrolled within the past 30 days)

Related Conditions & MeSH terms

• Cardiogenic Shock
• Shock
• Shock, Cardiogenic

Intervention

Device:
• IVTM™ System
TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
• Quattro® Catheter
TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.

Locations

Country	Name	City	State
United States	The University of Chicago	Chicago	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
University of Chicago	ZOLL Circulation, Inc., USA

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Episodes of Arrhythmia	requiring intervention (medical therapy or therapy with temporary pacemaker)	up to 96 hours
Primary	Number of Participants With Bleeding	requiring transfusions as a direct result of the cooling catheter insertion or secondary to resulting coagulopathy	up to 96 hours
Primary	Number of Participants With Bloodstream Infection/Suspected Sepsis	confirmed with 2 positive blood cultures or sequential organ failure assessment (SOFA) score >2	up to 96 hours
Primary	Number of Participants With Hypokalemia	potassium levels below 3.0mEq/L, not secondary to other identifiable causes	up to 96 hours
Secondary	Changes in Cardiac Index	Difference between groups in cardiac index and output	up to 96 hours
Secondary	Changes in Systemic Vascular Resistance (SVR)	Mean SVR in population	up to 96 hours
Secondary	Cardiac Power Index	Measured 48-96 hours after randomization	up to 96 hours
Secondary	Cumulative Milrinone Dose	cumulative weight adjusted dosing of milrinone	up to 96 hours
Secondary	Left Ventricular Ejection Fraction	percent ejection fraction on echocardiogram at 18-24 hours after randomization	up to 18-24 hours
Secondary	All-cause Mortality	All-cause mortality at 90 days was primary outcome/time point of choice.	up to 96 hours, 30 days, and 90 days
Secondary	Cumulative Dobutamine Dose	Cumulative dose of weight adjusted dobutamine dobutamine	96 hours
Secondary	Cumulative Dopamine Dose	Cumulative weight adjusted dopamine dose	96 hours